Personalized Cancer Therapy 


Founders, Senior Management and Board of Directors

The Founders and Management of Metaclipse are experienced and successful with careers in founding and building start-up companies, academia, and industry. The Company’s Founders constitute the members of the Board of Directors.

Shaker J.C. Reddy MS, President of Metaclipse and Chief Operating Officer.  He brings a strong leadership role to all of his varying responsibilities with his insights into effective business management. Mr. Reddy has participated in the creation and development of several companies. In 1988 he started his first company Accura, an analytical laboratory. He grew the company from inception to the third largest lab in the nation performing analysis on chemical and radiochemical samples. At Accura he implemented the method development and quality control systems necessary for rapid expansion. Accura was acquired by Xenco Laboratories. His second venture was Buildspan, an e-business to business marketplace for the hospital sector that was acquired by Paalam Technologies. At Buildspan he participated as an angel investor and gained valuable experience in venture capital funding. He co-founded his third business, Accura Engineering, which provides engineering services to the greater Atlanta area since 2003. In 2007 he started AccuRx Biopharma, a biotech firm developing a drug delivery platform in the ophthalmic space. Mr. Reddy founded Metaclipse Therapeutics in 2011 based on an Emory technology. His extensive experiences in entrepreneurial leadership, angel investment, laboratory management and fund raising give him the necessary background for leading the operations of Metaclipse Therapeutics

Periasamy Selvaraj, PhD, Chief Scientific Officer. He completed his postdoctoral training at Dana Farber Cancer Institute at Harvard Medical School then served on the faculty of Harvard University as an Instructor from 1988-1990. He was recruited to the Department of Pathology at Emory University School of Medicine in 1990. Since then he has been active in establishing research programs in autoimmunity and cancer immunotherapy. His laboratory developed and tested many novel immunotherapy approaches for treatment of cancer as well as Fc receptor-based therapies to treat autoimmune diseases. He has authored/co-authored more than 90 research articles in leading scientific journals and received many NIH grants.

Kamal V. Kannan, PhD, Vice President, Product Development. Dr. Kannan is a renowned scientist with over 25 years of process and analytical method development. He earned his PhD in Biochemistry from the University of Madras, India, and has since spent his career at small to mid-size pharmaceutical companies, including Dynavax Technologies, Takeda California, Five Prime Therapeutics, VaxGen, Elan Pharmaceuticals, and Genentech.   He is a seasoned analytical biochemist with expertise in analytical, formulation, clinical quality control and vaccine development.  He has contributed to the development of six FDA approved biopharmaceuticals (Rituximab®, Herceptin®, Tysabri®, OncoScint®, ProstaScint® and Myobloc®) and five INDs. His strengths include protein analytical methods development, characterization, qualification, validation, clinical quality control, establishing specifications, protein formulation, in-process assays, GMP/GLP compliance, regulatory agency liaison including EMEA (European Medicine Evaluation Agency) as well as compliance with FDA (Food and Drug Administration) inspections.


Christopher D. Pack, PhD, Director, Preclinical Studies. Dr. Pack is leading preclinical research and responsible for liaising with Dr. Selvaraj’s lab. Dr. Pack has extensive training and expertise in vaccine design and CD8 T cell biology.  He received his PhD from the University of Tennessee where he studied neonatal vaccine design against Herpes Simplex Virus-1 in the laboratory of Dr. Barry T. Rouse. Dr. Pack recently completed a postdoctoral fellowship in Dr. Aron Lukacher’s laboratory at Emory University School of Medicine. His research focused on priming and functional differences of CD8 T cells over the course of a cancer causing persistent viral infection.  Many of the same hurdles to generate effective immunity are shared between persistent viral infections and cancer.

Sampath Ramachandiran, PhD, Technical Leader, Product Development. Dr. Ramachandiran is leading product development and protein purification. He received his PhD  in biochemistry from Indian Institute of Science. His dissertation focused on purification and cloning of a novel alpha amylase. Specific areas of expertise include protein purification, signaling mechanisms, molecular diagnosis of diseases, molecular genetics, molecular toxicology, cell and biochemical assays to develop novel drugs.